{"title":"Thyroid Storm Following Alemtuzumab-based Allogeneic Stem Cell Transplantation: A Case Report and Literature Review.","authors":"Sakura Saigusa, Kaori Uchino, Hideshige Seki, Yukie Sugita, Yuto Isaji, Yusuke Iida, Saki Shinohara, Tomohiro Horio, Satsuki Murakami, Shohei Mizuno, Kazuhiro Ikegame, Ichiro Hanamura, Junichiro Mokuno, Junko Takagi, Daiki Hirano, Hiroatsu Iida, Shinji Nakao, Akiyoshi Takami","doi":"10.2169/internalmedicine.5587-25","DOIUrl":null,"url":null,"abstract":"<p><p>Alemtuzumab-based conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT) effectively reduces graft rejection but may predispose patients to autoimmune complications. We herein report a 30-year-old man with severe aplastic anemia who developed thyroid storm due to autoimmune thyroiditis 6 months after undergoing allo-HSCT with an alemtuzumab-based regimen. Despite prompt engraftment, mixed T-cell chimerism and insufficient immune regulation may have contributed to the early onset and severity of the thyroid storm. Careful monitoring of the thyroid function and immune chimerism might facilitate the early detection and management of post-transplant autoimmune complications, including thyroid storm, in patients receiving alemtuzumab-based conditioning.</p>","PeriodicalId":520650,"journal":{"name":"Internal medicine (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal medicine (Tokyo, Japan)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2169/internalmedicine.5587-25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Alemtuzumab-based conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT) effectively reduces graft rejection but may predispose patients to autoimmune complications. We herein report a 30-year-old man with severe aplastic anemia who developed thyroid storm due to autoimmune thyroiditis 6 months after undergoing allo-HSCT with an alemtuzumab-based regimen. Despite prompt engraftment, mixed T-cell chimerism and insufficient immune regulation may have contributed to the early onset and severity of the thyroid storm. Careful monitoring of the thyroid function and immune chimerism might facilitate the early detection and management of post-transplant autoimmune complications, including thyroid storm, in patients receiving alemtuzumab-based conditioning.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
